IBX Share Price Performance
AU$0.015
-0.02 (-54.55%)
Price AU$0.015
Share PriceAU$0.015
IBX Community Narratives
There are no narratives available yet.
Recent IBX News & Updates
No updates
Imagion Biosystems Limited Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.01
- Gross Margin
- 84.95%
- Net Profit Margin
- -77.56%
- Debt/Equity Ratio
- -122.4%
Imagion Biosystems Limited Competitors
About IBX
- Founded
- 2016
- Employees
- n/a
- CEO
- WebsiteView website
Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It is involved in the nanotechnology; biotechnology; and cancer diagnostics businesses. The company develops MagSense, which completed Phase 1 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to detect cancer. The company has collaboration with Siemens MRI to support the Phase 2 study of MagSense HER2 imaging agent. Imagion Biosystems Limited was incorporated in 2016 and is based in Melbourne, Australia.
Australian Market Performance
- 7 Days: 1.2%
- 3 Months: 7.7%
- 1 Year: 15.0%
- Year to Date: 7.3%
The market is up 1.2% over the last week, with the Materials sector leading the way, up 4.0%. As for the past 12 months, the market is up 15%. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading